Ann: Proposed issue of Securities - IMU, page-21

Classic movie, but really I think you just mis read the SOI, it's 4.93B as in billion.
So 15million is but a drop with further 182million to be converted by November this year and 171 by Nov next year bringing in a further 16million to the company to continue to fund all current trials.

If this ammount of shares on issue seems excessive, then you haven't done your research as to what has been bought and funded with it to get IMU to this point.

For those playing along at home;
Her-Vaxx vs Herceptin. Phase 2 readout or PFS due in coming weeks.
PD1-VAX vs Keytruda PD1-VAX cohort 3 max dose safety due shortly.

CF33 vs the full NCI-60 cancer list, in pre clinical trials.
FDA IND application approval or feedback should be in next few weeks.